Sharekhan

Venus Remedies Ltd

Fri 18/07/2025,15:58:55 | NSE : VENUSREM

₹ 552.60-0.20 (-0.04%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 555.00

Previous Close

₹ 552.80

Volume

63656

Mkt Cap ( Rs. Cr)

₹738.66

High

₹ 567.80

Low

₹ 525.20

52 Week High

₹ 567.80

52 Week Low

₹ 270.25

Book Value Per Share

₹ 369.73

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Venus Remedies Ltd

Your Vote -

Buy

43.75%

Hold

18.75%

Sell

37.50%

43.75%

16 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Venus Remedies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Venus Remedies L has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025

    19 Jul 2025, 7:05AM As of June 2025, 41.76% is owned by Indian Promoters and 58.24% by Public. <p align=justify> Top three Promoters holding highest number of shares of V
  • Venus Remedies L - Structural Digital Database

    17 Jul 2025, 11:54AM For the quarter ended on 30th June 2025
  • Venus Remedies L - Copy of Newspaper Publication

    11 Jul 2025, 12:23PM Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication
  • Venus Remedies L - Board Meeting Outcome for Outcome Of Board Meeting Dated 8Th July 2025.

    8 Jul 2025, 6:00PM approved as below:\r\n1. The date of 36th Annual General Meeting fixed as 22nd August 2025 at 11:30 a.m. (1ST) through Video Conferencing (\VC\) I Oth
  • Venus Remedies L - Outcome of Board Meeting

    8 Jul 2025, 5:58PM Venus Remedies Limited has informed the Exchange regarding Board meeting held on July 08, 2025.
  • Venus Remedies L - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Jul 2025, 10:29AM Venus Remedies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
  • Venus Remedies L - Updates

    8 Jul 2025, 10:27AM Venus Remedies Limited has informed the Exchange regarding compliance under regulation 74(5) of SEBI DP regulations for the quarter ended on 30th June
  • Venus Remedies L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Jul 2025, 10:23AM Compliance under regulation 74(5) of SEBI DP regulations for the quarter ended on 30th June 2025.
  • Venus Remedies L - Board Meeting Intimation

    27 Jun 2025, 5:16PM Venus Remedies Limited has informed the Exchange about Board Meeting to be held on 08-Jul-2025 to consider Other business.
  • Venus Remedies L - Board Meeting Intimation for Notice Of Board Meeting To Be Held On 8Th July 2025

    27 Jun 2025, 12:41PM Venus Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/07/2025 ,inter alia, to consider and a
  • Venus Remedies L - Trading Window

    24 Jun 2025, 10:39AM Venus Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Venus Remedies L - Trading Window-XBRL

    24 Jun 2025, 10:19AM Venus Remedies Limited has informed the Exchange about Closure of Trading Window
  • Venus Remedies L - Trading Window

    24 Jun 2025, 10:12AM Venus Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Venus Remedies L - Disclosure under SEBI Takeover Regulations

    13 Jun 2025, 6:45PM Venus Remedies Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substa
  • Venus Remedies L - Copy of Newspaper Publication

    29 May 2025, 10:09AM Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication of Financial Results
  • Venus Remedies L - Copy of Newspaper Publication

    28 May 2025, 11:17PM Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication
  • Venus Remedies L Q4 net profit up 18.13% at Rs 14.79 cr

    27 May 2025, 10:02AM The company reported standalone net profit of Rs 14.79 crore for the quarter ended March 31, 2025 as compared to Rs 12.52 crore in the same period las
  • Venus Remedies L - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    26 May 2025, 10:50PM VENUS REMEDIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agen
  • Venus Remedies L - Announcement under Regulation 30 (LODR)-Change in Management

    26 May 2025, 10:35PM As per pdf enclosed
  • Venus Remedies L - Change in Management

    26 May 2025, 10:34PM Venus Remedies Limited has informed the Exchange about change in Management
  • Venus Remedies L - Outcome of Board Meeting

    26 May 2025, 10:31PM Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
  • Venus Remedies L - Audited Financial Results As On 31.03.2025

    26 May 2025, 10:30PM As per the pdf attached.
  • Venus Remedies L - Outcome of Board Meeting

    26 May 2025, 10:22PM Venus Remedies Limited has informed the Exchange regarding Board meeting held on May 26, 2025.
  • Venus Remedies L - Board Meeting Outcome for Outcome Of Board Meeting Dated 26.05.2025.

    26 May 2025, 10:22PM AS per enclosed pdf.\r\n
  • Venus Remedies L - Updates

    22 May 2025, 10:01AM Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence
  • Venus Remedies secures Ukrainian GMP Renewal, Boosting Global Pharmaceutical Expansion

    22 May 2025, 10:13AM Venus Remedies Limited, a prominent global pharmaceutical company, has successfully renewed its Good Manufacturing Practices (GMP) certification from
  • Venus Remedies L - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    22 May 2025, 9:57AM Venus Remedies Secures Ukrainian GMP Renewal, Strengthening Global Pharmaceutical Presence.
  • Venus Remedies L - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    22 Apr 2025, 2:02PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td
  • Venus Remedies secures Marketing Authorization in Philippines

    6 Dec 2024 , 2:55PM Pemetrexed is a type of chemotherapy used in the treatment of lung cancer
  • Venus Remedies achieves major milestone with UNICEF

    13 Jun 2024 , 2:04PM Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.
  • Venus Remedies gets new marketing nod for two drugs in Europe

    12 Jan 2024 , 12:38PM Venus Remedies gets new marketing authorisations for Docetaxel & Gemcitabine from Malta, Europe
  • Venus Remedies secures marketing authorisations for Docetaxel and Cytarabine

    21 Dec 2023 , 2:22PM Venus Remedies achieves marketing authorizations for Docetaxel in Israel and Cytarabine in Colombia
  • Venus Remedies Consumer Healthcare Division, R3SET forays into wellness segment

    20 Dec 2023 , 12:03PM Venus Remedies R3SET takes strategic lap into wellness with holistic health Innovations
  • Venus Remedies receives market authorisations for Enoxaparin in Azerbaijan

    5 Dec 2023 , 11:37AM Enoxaparin is used to prevent and treat harmful blood clots
  • Venus Remedies grant market authorisations in Saudi Arabia and Philippines

    1 Dec 2023 , 12:19PM Venus Remedies gets marketing authorisations for Paclitaxel & Zolendronic acid in the Philippines & for Bleomycin 15lU in Saudi Arabia
  • Venus Remedies arm gets authorization to market Cancer Drug in UK

    26 Oct 2023 , 11:40AM Venus Remedies granted martket authorisation for Bleomycin 15000 IU in UK
  • Venus Remedies gets marketing nod for six chemotherapy drugs from Philippines

    16 Oct 2023 , 10:46AM Secures 525 marketing approvals for its oneology products across 76 Countries.
  • Venus Remedies extends its oncology portfolio in South Eastern Europe

    20 Sep 2023 , 10:48AM Venus Remedies gets Serbian marketing nod for Gemcitabine & Docetaxel, extends oncology portfolio in South Eastern Europe
  • Venus Remedies on expansion spree in Gulf

    28 Aug 2023 , 12:25PM Venus Remedies gets marketing approval from Saudi Arabia for its product Enoxaparin in pre-filled syringes
  • Venus Remedies oncology wing product registration go upto 506

    31 Jul 2023 , 11:23AM Venus Remedies gets marketing nod for cancer drugs from Philippines, Paraguay, Georgia & Moldova
  • Venus Remedies gets marketing nod for chemo drug.

    5 Jul 2023 , 12:55PM Venus Remedies gets marketing nod from Oman, Malaysia, Bosnia & Trinidad & Tobago for chemo drug
  • Venus Remedies bags nod to market Meropenem, its block buster generic drug, in Spain

    22 Jun 2023 , 11:43AM Venus Remedies German arm gets Spanish regulator nod to market Meropenem, a broad-spectrum antibiotic in Spain
  • Venus Remedies gets Ukrainian GMP nod

    7 Jun 2023 , 11:22AM Venus Remedies gets Ukrainian GMP nod for its Carbapenem, Oncology parenteral facilities
  • Venus Remedies bags Saudi GMP nod for all its production facilities

    27 Feb 2023 , 10:12AM Venus Remedies gets Saudi GMP nod for all its production facilities in Baddi.
  • Venus Remedies

    9 Dec 2021 , 11:31AM Venus Remedies: Gets approval from the Government of India for PLI scheme. The company has received an approval under category C of the PLI scheme and is eligible for incentives for FY2022-23 to FY2027-28 subject to fulfilment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines, Hence Positive.
  • Venus Remedies enters into partnership with West Pharmaceutical Service

    13 Apr 2021 , 1:29PM Venus Remedies enters into partnership with West Pharmaceutical Services to Launch Cloti-Xa (Enoxaparin Prefilled Syringes) in India

Key fundamentals

Evaluate the intrinsic value of Venus Remedies Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 589.5 547.2703 516.7264 488.0923 447.7034
Liabilities 589.5 547.2703 516.7264 488.0923 447.7034
Equity 13.37 13.367 13.367 13.367 12.342
Gross Profit 69.99 60.8913 61.5258 68.8218 46.8627
Net Profit 52.55 30.5004 28.9644 48.9866 54.2724
Cash From Operating Activities 83.1 35.3826 28.0548 40.8998 132.6673
NPM(%) 8.21 5.3 5.38 8.51 10.54
Revenue 639.46 575.2124 537.6619 575.181 514.623
Expenses 569.47 514.3211 476.1361 506.3592 467.7603
ROE(%) 10.63 6.17 5.86 9.91 10.98

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
3 30 0 279.5
23 Sep 2013 3 30 0 304.45
20 Sep 2012 3 30 0 228.05
22 Sep 2011 3 30 0 253.15
23 Sep 2010 3 30 0 268
17 Sep 2009 3 30 0 278.45
12 Sep 2008 4 40 0 400.85
18 Sep 2007 3 30 0 470.05

Peers

Other companies within the same industry or sector that are comparable to Venus Remedies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 933.30 0.89 30.97 314.55 301.39 0.54
Lotus Eye Hospital and Institute Ltd 75.41 1.51 215.46 1146.19 3.55 0.00
Vaishali Pharma Ltd 12.77 -1.69 212.83 590.79 3.13 0.00
Astec Lifesciences Ltd 901.45 -0.84 0.00 1080.88 -601.21 0.00

Company Info

M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

Read More

Parent Organisation

Venus Remedies Ltd.

Founded

15/09/1989

Managing Director

Mr.Pawan Chaudhary

NSE Symbol

VENUSREMBE

FAQ

The current price of Venus Remedies Ltd is ₹ 552.60.

The 52-week high for Venus Remedies Ltd is ₹ 567.80 and the 52-week low is ₹ 525.20.

The market capitalization of Venus Remedies Ltd is currently ₹ 738.66. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Venus Remedies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Venus Remedies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Venus Remedies Ltd shares.

The CEO of Venus Remedies Ltd is Mr.Pawan Chaudhary, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT